Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00344617
Verified September 2007 by Singapore National Eye Centre. Recruitment status was: Active, not recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
50 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All subfoveal/juxtafoveal CNV and PCV (polypoidal choroidal vasculopathy) who are not eligible for other treatment options (compassionate use)
CNV and PCV lesions which have failed PDT, conventional argon laser photocoagulation (salvage use)
CNV and PCV lesions treatable with PDT, but cannot afford or refused
Patients with uncontrolled hypertension (systolic BP greater than 150mmHg or diastolic BP greater than 90mmHg
History of thrombolic events such as myocardial infarction or cerebral vascular accident
Renal abnormalities (as defined by established history of chronic renal disease or renal failure as well as patients requiring dialysis).
Recent (as defined as the past 28 days) or planned (as defined as the next 3 months) surgery.
Coagulation abnormalities, including anti-coagulant medication other than aspirin